# A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

> **NCT07682272** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

## Interventions

- **DRUG:** SHR-8068 Injection
- **DRUG:** Adebrelimab Injection
- **DRUG:** Apatinib Mesylate Tablets

## Key facts

- **NCT ID:** NCT07682272
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682272, "A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07682272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*